Our study predicts that drugs such as cisplatin, pilocarpine hydrochloride, cetuximab, and epirubicin may target hub genes including MAPK3, TP53, MMP9, and FOS, suggesting a potential therapeutic strategy for immune dysfunction-related diseases, including HIV infection. The gene discussed is TP53; the disease is HIV infectious disease.